The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria

Authors

  • Martin Danis,

    Corresponding author
    1. Service de Parasitologie-Mycologie and Unité INSERM 511, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Paris 6, 47 bd de l'Hôpital, 75651 Paris cedex 13, France
      *Correspondence and reprints: Service de Parasitologie- Mycologie and Unité INSERM 511, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 bd de l'Hôpital, 75651 Paris cedex 13, France
    Search for more papers by this author
  • François Bricaire

    1. Service de Parasitologie-Mycologie and Unité INSERM 511, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Paris 6, 47 bd de l'Hôpital, 75651 Paris cedex 13, France
    Search for more papers by this author

*Correspondence and reprints: Service de Parasitologie- Mycologie and Unité INSERM 511, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 bd de l'Hôpital, 75651 Paris cedex 13, France

Abstract

Malaria is a leading cause of morbidity and mortality in developing countries. Selection of mutant Plasmodium falciparum malaria strains under drug pressure has led to the development of drug resistance. There is a pressing need for effective, safe, practicable drug combinations that hve lower selection pressure. A review of the mein drug combinations, which are recently registered or are still under development, was undertaken, with special attention to the atovaquone–proguanil and artemether–lumefantrine combination.

Ancillary